B7-CD28免疫检查点家族的第三组：HHLA2、TMIGD2、B7x和B7-H3。
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
作者信息
Janakiram Murali, Shah Urvi A, Liu Weifeng, Zhao Aimin, Schoenberg Mark P, Zang Xingxing
机构信息
Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
出版信息
Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521.
Abstract
The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.
摘要
B7 - CD28配体与受体家族在T细胞共刺激和共抑制中发挥着重要作用。从系统发育角度来看，它们可分为三组。近期第三组新分子（B7 - H3 [CD276]、B7x [B7 - H4/B7S1]以及HHLA2 [B7H7/B7 - H5]/TMIGD2 [IGPR - 1/CD28H]）的发现，为人类疾病的治疗拓展了治疗可能性。在这篇综述中，我们描述了B7 - H3、B7x、HHLA2和TMIGD2在免疫调节中的发现、结构及功能。我们还讨论了它们在诸如癌症、自身免疫性疾病、移植和感染等重要病理状态中的作用。包括拮抗单克隆抗体和激动性融合蛋白在内的各种免疫治疗方法正在兴起，以抑制或增强癌症和自身免疫性疾病中这些分子及信号通路的作用。
相似文献
1
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.B7-CD28免疫检查点家族的第三组：HHLA2、TMIGD2、B7x和B7-H3。
Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521.
2
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.HHLA2 是 B7 家族的一员，可抑制人 CD4 和 CD8 T 细胞的功能。
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84. doi: 10.1073/pnas.1303524110. Epub 2013 May 28.
3
TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.TOP 嵌合抗原受体（CAR）细胞以 TMIGD2 作为安全有效的共刺激结构域治疗人实体瘤。
Sci Adv. 2024 May 10;10(19):eadk1857. doi: 10.1126/sciadv.adk1857. Epub 2024 May 8.
4
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.B7/CD28 免疫检查点家族的最新进展：新的生物学和临床治疗策略。
Cell Mol Immunol. 2023 Jul;20(7):694-713. doi: 10.1038/s41423-023-01019-8. Epub 2023 Apr 17.
5
Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.基于 B7-H3、B7-H4 和 HHLA2 的新型免疫评分动态列线图：对胆囊癌生存和免疫治疗疗效的潜在预测。
Front Immunol. 2022 Sep 8;13:984172. doi: 10.3389/fimmu.2022.984172. eCollection 2022.
6
The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.人类内源性逆转录病毒-H 长末端重复序列相关蛋白 2 和跨膜及免疫球蛋白域包含 2 在口腔鳞状细胞癌中的表达模式及相关临床参数。
Dis Markers. 2019 Apr 7;2019:5421985. doi: 10.1155/2019/5421985. eCollection 2019.
7
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.B7x 和 HHLA2 等免疫检查点分子在 PD-L1 阴性人肺癌中的广泛表达及意义。
Clin Cancer Res. 2018 Apr 15;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924. Epub 2018 Jan 26.
8
New checkpoints in cancer immunotherapy.癌症免疫疗法中的新检查点。
Immunol Rev. 2017 Mar;276(1):52-65. doi: 10.1111/imr.12524.
9
KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.KIR3DL3-HHLA2 和 TMIGD2-HHLA2 途径：HHLA2 在免疫反应中的双重作用及其在癌症免疫治疗中的潜在治疗方法。
J Adv Res. 2023 May;47:137-150. doi: 10.1016/j.jare.2022.07.013. Epub 2022 Aug 4.
10
The Importance of HHLA2 in Solid Tumors-A Review of the Literature.HHLA2 在实体瘤中的重要性——文献综述
Cells. 2024 May 7;13(10):794. doi: 10.3390/cells13100794.
引用本文的文献
1
Preliminary screening of urinary host protein biomarkers for Schistosomiasis haematobium: A proteome profiling study identifying candidate diagnostic targets in school-aged children.埃及血吸虫病尿液宿主蛋白质生物标志物的初步筛选：一项蛋白质组分析研究，确定学龄儿童中的候选诊断靶点。
PLoS Negl Trop Dis. 2025 Aug 25;19(8):e0013429. doi: 10.1371/journal.pntd.0013429. eCollection 2025 Aug.
2
p62/SQSTM1 impairs immunotherapy in lung adenocarcinoma by suppressing immune infiltration and peripheral immune response.p62/SQSTM1 通过抑制免疫浸润和外周免疫反应损害肺腺癌的免疫治疗。
Biochem Biophys Rep. 2025 Jul 14;43:102139. doi: 10.1016/j.bbrep.2025.102139. eCollection 2025 Sep.
3
Research progress of B7-H3 in malignant tumors.B7-H3在恶性肿瘤中的研究进展
Front Immunol. 2025 May 30;16:1586759. doi: 10.3389/fimmu.2025.1586759. eCollection 2025.
4
HHLA2: a potential biomarker and therapeutic target in endocrine-related cancer.HHLA2：内分泌相关癌症中的一种潜在生物标志物和治疗靶点。
Endocr Oncol. 2025 Apr 7;5(1):e240034. doi: 10.1530/EO-24-0034. eCollection 2025 Jan.
5
Construction of a risk model associated with tryptophan metabolism and identification of related molecular subtypes in laryngeal squamous cell carcinoma.构建与色氨酸代谢相关的风险模型并鉴定喉鳞状细胞癌中的相关分子亚型
Front Genet. 2025 Mar 24;16:1530334. doi: 10.3389/fgene.2025.1530334. eCollection 2025.
6
Immune checkpoint blockade for cancer therapy: current progress and perspectives.用于癌症治疗的免疫检查点阻断：当前进展与展望。
J Zhejiang Univ Sci B. 2025 Mar 13;26(3):203-226. doi: 10.1631/jzus.B2300492.
7
Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies.慢性乙型肝炎中T细胞和B细胞的功能障碍及调节相互作用：免疫疗法与新兴抗病毒策略
Front Cell Infect Microbiol. 2024 Dec 9;14:1488527. doi: 10.3389/fcimb.2024.1488527. eCollection 2024.
8
Harnessing 2D and 3D human endometrial cell culture models to investigate SARS-CoV-2 infection in early pregnancy.利用二维和三维人类子宫内膜细胞培养模型研究妊娠早期的新冠病毒感染
Clin Sci (Lond). 2025 Feb 19;139(4):CS20241215. doi: 10.1042/CS20241215.
9
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies.胶质母细胞瘤及其他疾病中的B7-H3：意义与治疗策略
Front Immunol. 2024 Nov 25;15:1495283. doi: 10.3389/fimmu.2024.1495283. eCollection 2024.
10
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.恩杂鲁胺在前列腺癌治疗中的应用及耐药机制。
Expert Rev Anticancer Ther. 2024 Nov;24(11):1085-1100. doi: 10.1080/14737140.2024.2405103. Epub 2024 Sep 20.
本文引用的文献
1
HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.HHLA2，B7家族的一个新的免疫检查点成员，在人类肺癌中广泛表达并与表皮生长因子受体（EGFR）突变状态相关。
Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.
2
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.HHLA2是B7家族的一员，在人类骨肉瘤中表达，并与转移及较差的生存率相关。
Sci Rep. 2016 Aug 17;6:31154. doi: 10.1038/srep31154.
3
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.PD-L1、IDO-1和B7-H4在人肺癌中的差异表达及意义
Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.
4
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.B7-H4嵌合抗原受体T细胞疗法后的肿瘤消退和延迟性毒性
Mol Ther. 2016 Nov;24(11):1987-1999. doi: 10.1038/mt.2016.149. Epub 2016 Jul 21.
5
B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma.B7-H4表达提示口腔鳞状细胞癌预后不良。
Cancer Immunol Immunother. 2016 Sep;65(9):1035-45. doi: 10.1007/s00262-016-1867-9. Epub 2016 Jul 6.
6
Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.免疫检查点阻断在人类癌症治疗中的应用：肺癌和血液系统恶性肿瘤
Immunotherapy. 2016 Jun;8(7):809-19. doi: 10.2217/imt-2016-0001.
7
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.分子途径：靶向B7-H3（CD276）用于人类癌症免疫治疗
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431. doi: 10.1158/1078-0432.CCR-15-2428. Epub 2016 May 20.
8
Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.B7-H4与乙型肝炎病毒X在乙型肝炎病毒相关性肝细胞癌中的表达
World J Gastroenterol. 2016 May 14;22(18):4538-46. doi: 10.3748/wjg.v22.i18.4538.
9
B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.B7-H4（B7x）通过IL6/JAK/STAT3通路介导的胶质瘤起始细胞与巨噬细胞之间的串扰导致胶质瘤患者预后不良。
Clin Cancer Res. 2016 Jun 1;22(11):2778-2790. doi: 10.1158/1078-0432.CCR-15-0858. Epub 2016 Mar 21.
10
B7-H3 expression associates with tumor invasion and patient's poor survival in human esophageal cancer.B7-H3表达与人类食管癌的肿瘤侵袭及患者的不良生存相关。
Am J Transl Res. 2015 Dec 15;7(12):2646-60. eCollection 2015.
Zotero 插件